Aspen Racing Stables

Kun Run Biotechnology, formerly known as Aspen Racing Stables, is a leading Chinese biopharmaceutical company specializing in the development, manufacture, and commercialization of therapeutic peptides. Operating primarily through its subsidiary, Hainan Zhonghe Pharmaceutical, the company was a pioneer in the Chinese peptide industry and launched the nation's first modern peptide drug, Thymopentin (TP-5). Kun Run's extensive portfolio covers therapeutic areas such as immunology, oncology, infectious diseases, and gastroenterology, with products ranging from immunomodulators to treatments for hepatitis and diabetes. The company utilizes advanced solid-phase peptide synthesis (SPPS) technology and maintains large-scale GMP-certified manufacturing facilities in Haikou, China. Following a reverse merger in 2008, the company has established a significant market presence both domestically and internationally.